The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of topotecan, cisplatin, and bevacizumab for recurrent or persistent cervical cancer.
Israel Zighelboim
Research Funding - Genentech; GlaxoSmithKline
Jason D. Wright
Research Funding - Genentech
Feng Gao
No relevant relationships to disclose
Ashley Stephens Case
No relevant relationships to disclose
L. Stewart Massad
No relevant relationships to disclose
David Gardner Mutch
Research Funding - Genentech; Lilly
Expert Testimony - Coleman v Roth*; Cornellius v Jacobs*
Matthew A. Powell
Honoraria - Genentech; GlaxoSmithKline
Research Funding - Genentech; GlaxoSmithKline
Premal H. Thaker
No relevant relationships to disclose
Eric Lawernce Eisenhauer
No relevant relationships to disclose
David E. Cohn
No relevant relationships to disclose
Fidel A. Valea
No relevant relationships to disclose
Angeles Alvarez Secord
Research Funding - GlaxoSmithKline
Lynne T. Lippmann
No relevant relationships to disclose
Janet Sue Rader
No relevant relationships to disclose